PTD 在急性髓系白血病患者中的预后意义：系统评价和荟萃分析。
Prognostic significance of PTD in patients with acute myeloid leukaemia: a systematic review and meta-analysis.
机构信息
Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Department of Outpatient, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, China.
出版信息
BMJ Open. 2023 Feb 1;13(2):e062376. doi: 10.1136/bmjopen-2022-062376.
OBJECTIVES
Whether -PTD has a prognostic impact on patients with acute myeloid leukaemia (AML) is controversial. Therefore, we conducted a meta-analysis to assess the prognostic value of -PTD in patients with AML.
METHODS
Eligibility criteria: we included studies concerning the prognostic value of -PTD in patients with AML.
INFORMATION SOURCES
Eligible studies were identified from PubMed, Embase, Medline, Web of Science, Cochrane Library and Chinese Biomedical Database. The systematic search date was 19 December 2020.Risk of bias: Sensitivity analysis was used to evaluate the stability and reliability of the combined results. Begg's and Egger's tests were used to assess the publication biases of studies.
SYNTHESIS OF RESULTS
We calculated the pooled HRs and their 95% CIs for overall survival (OS) and event-free survival (EFS) by Stata V.12 software.
RESULTS
Included studies: 18 studies covering 6499 patients were included.
SYNTHESIS OF RESULTS
-PTD conferred shorter OS in total population (HR=1.30, 95% CI 1.09 to 1.51). In the subgroup analysis, -PTD also resulted in shorter OS in karyotypically normal AML patients (HR=2.72, 95% CI 1.83 to 3.61) and old AML patients (HR=1.93, 95% CI 1.44 to 2.42). -PTD indicated no prognostic impact on EFS in total population (HR=1.26, 95% CI 0.86 to 1.66). However, in the sensitivity analysis, -PTD resulted in poor EFS (HR=1.34, 95% CI 1.04 to 1.64) when deleting the study with a relatively obvious effect on the combined HR. In the subgroup analysis, -PTD was associated with poor EFS in old AML patients (HR=1.64, 95% CI 1.25 to 2.03).
CONCLUSION
The findings indicated that -PTD had an adverse impact on the prognosis of patients with AML in the total population, and the conclusion can also be applied to some subgroups including karyotypically normal AML and old AML patients. -PTD may be a promising genetic biomarker in patients with AML in the future.
TRIAL REGISTRATION NUMBER
CRD42021227185.
目的
-PTD 对急性髓系白血病（AML）患者的预后是否有影响存在争议。因此，我们进行了一项荟萃分析，以评估-PTD 在 AML 患者中的预后价值。
方法
纳入标准：纳入研究-PTD 对 AML 患者预后价值的研究。
信息来源
从 PubMed、Embase、Medline、Web of Science、Cochrane 图书馆和中国生物医学数据库中确定合格的研究。系统搜索日期为 2020 年 12 月 19 日。偏倚风险：采用敏感性分析评估合并结果的稳定性和可靠性。采用 Begg 和 Egger 检验评估研究的发表偏倚。
结果
我们使用 Stata V.12 软件计算总生存率（OS）和无事件生存率（EFS）的合并 HRs 及其 95%CI。
结果
纳入的研究：18 项研究共纳入 6499 例患者。
结果
-PTD 使总体人群的 OS 更短（HR=1.30，95%CI 1.09 至 1.51）。在亚组分析中，-PTD 在核型正常 AML 患者（HR=2.72，95%CI 1.83 至 3.61）和老年 AML 患者（HR=1.93，95%CI 1.44 至 2.42）中也导致 OS 更短。-PTD 对总人群的 EFS 无预后影响（HR=1.26，95%CI 0.86 至 1.66）。然而，在敏感性分析中，当删除对合并 HR 有明显影响的研究时，-PTD 导致 EFS 较差（HR=1.34，95%CI 1.04 至 1.64）。在亚组分析中，-PTD 与老年 AML 患者的 EFS 较差相关（HR=1.64，95%CI 1.25 至 2.03）。
结论
研究结果表明，-PTD 对 AML 患者的总体预后有不良影响，该结论也适用于核型正常 AML 和老年 AML 患者等亚组。-PTD 可能成为 AML 患者有前途的遗传生物标志物。
临床试验注册号
CRD42021227185。
Zotero 插件